← Russell 3000 cross-section

TMDX TransMedics Group, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$3.2bn
Revenue TTM
$668m
Net income TTM
$152m
Free cash flow
$79m
Composite score
57.1
Sector rank
#1352

Valuation

P / E
21.2
EV / EBITDA
27.3
EV / sales
4.8
FCF yield
2.46%
Earnings yield vs 10-yr
-0.02pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
22.7%
EBITDA margin
17.7%
ROE
29.3%
ROIC
15.8%
Revenue growth
25.8%

Insider activity, last 90 days

Net open-market
$-0.72m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

To date, we have funded our operations primarily with proceeds from borrowings under loan agreements, proceeds from the issuance of the Notes, proceeds from the sale of common stock in our public offerings, and revenue from commercial sales of our OCS products and NOP services and from sales of our OCS products for use in clinical trials. We expect our operating and capital expenditures will continue to increase as we focus on growing commercial sales of our products in both the United States and select non-U.S. markets. For example, tariffs related to a small portion of components that we import moderately increased our cost of revenue in 2025. …TransMedics Group, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →